![]() |
FDA-Approved Afrezza: An Inhaled Alternative to Injecta...
October 1, 2014 - Featured , In the News / Politics By: Elissa Tam, PharmD Candidate c/o 2015 – Patients with Type 1 or Type 2 diabetes who cannot control their glucose levels simply by taking oral medications have to inject insulin daily. They also have to measure their glucose levels by using strips and lancets on a regular basis. For patients, especially elderly ones, the… |
![]() |
Two New Agents for the Treatment of Obesity...
August 1, 2013 - Clinical , Featured By: Nathan Trustman, PharmD Candidate c/o 2013, AMSCOP at LIU – Obesity is defined as having a body mass index (BMI) of 30 kg/m2 or greater. It is thought to be the result of an imbalance between energy intake and energy expenditure, possibly due to a number of genetic and environmental factors.1 It is estimated… |
![]() |
Purple Glove Syndrome...
May 1, 2013 - Clinical , Featured By: Sharon Janak, PharmD Candidate c/o 2013 – How can we distinguish between vascular injury and Purple Glove Syndrome (an adverse effect of phenytoin)? What are the warning signs and symptoms? Phenytoin is an anticonvulsant used to treat generalized tonic-clonic and partial seizures. It stabilizes neuronal cell membranes of the motor cortex by facilitating the… |
![]() |
Merck Settles Lawsuits Over Vytorin...
April 1, 2013 - In the News / Politics By: Tasnima Nabi, Staff Editor – Merck & Co. will pay $688 million to settle two lawsuits filed in December 2008 over their patent-protected statin, Vytorin®. The suits state that Merck and Schering-Plough delayed releasing the results of their ENHANCE study to avoid a decrease in revenue.1 Vytorin® is a combination drug of simvastatin and… |
![]() |
New P2Y12 Antagonist on the Rise...
April 1, 2013 - Clinical By Nancy Rizkalla, PharmD candidate c/o 2015 – Percutaneous coronary intervention (PCI) with subsequent stent implantation is a highly effective approach in reducing the risk of death or ischemic complications following a myocardial infarction as well as improving the quality of life in patients with stable angina. PCI is ultimately performed in 60 –… |
![]() |
Giving a Second Chance: The Prescription Drug Abuse Epi...
December 1, 2012 - Featured , In the News / Politics , Professional Advice / Opinions By: Maria Sorbera, PharmD Candidate c/o 2013 at AMSCOP (LIU) – Author William S. Burroughs states in his novel, “The question is frequently asked: Why does a man become a drug addict? The answer is that he usually does not intend to become an addict. You don’t wake up one morning and decide to be… |
![]() |
Studying Abroad: The Perspective From a Pharmacy Studen...
October 1, 2012 - Professional Advice / Opinions By: Shannon Tellier – When applying to St. John’s University College of Pharmacy and Health Sciences five years ago, I never would have dreamed that I would have the opportunity to study abroad twice while obtaining my PharmD degree. At the end of my freshmen year, there were rumors about second year pharmacy students having… |
![]() |
Understanding Diabetic Ketoacidosis...
July 1, 2012 - Clinical , Featured By: Mohamed Dungersi, Associate Student Editor – What is diabetic ketoacidosis (DKA)? Diabetic ketoacidosis (DKA) is an acute complication of uncontrolled diabetes or hyperglycemia. It is usually observed in cases of extreme hyperglycemia (usually in excess of 500 mg/dl, though it can occur over 250 mg/dl).1,2 It is usually characterized by the presence of hyperglycemia,… |
![]() |
Effect of Intravenous Ondansetron on QT Interval Prolon...
June 1, 2012 - Clinical By: Raymond Wu, Pharm.D. Candidate c/o 2013 The 5-hydroxytryptamine type 3 (5HT3) antagonists (e.g. ondansetron [Zofran®]) are commonly used in the prevention and treatment of nausea and vomiting in the inpatient setting.1 Overall, ondansetron is a well-tolerated medication with few side effects.1 Constipation, dizziness, and headache are the most commonly reported side effects associated… |
![]() |
Update: FTC Approves Medco and Express Scripts Merger...
May 1, 2012 - Featured , In the News / Politics By: Mahdieh Danesh Yazdi, with Special Thanks to: Dr. Tomasz Jodlowski – In previous issues, we discussed an upcoming $29.1 billion merger between Express Scripts Inc. and Medco Health Solutions. The merger had been previously delayed by the Federal Trade Commission (FTC). The FTC wanted to verify that this upcoming merger would not violate any antitrust… |
![]() |
Bydureon®: A Weekly Injection for Type 2 Diabetes Mell...
February 1, 2012 - Clinical , Featured , In the News / Politics By: Mohamed Dungersi – On January 27, the FDA approved Bydureon® (exenatide extended-release) for use in Type 2 Diabetes Mellitus (T2DM), as an adjunct to diet and exercise. Bydureon®, a product of Amylin Pharmaceuticals, is a modified formulation of the twice-daily injection, Byetta® (exenatide). It is the first once-a-week medication for T2DM in the market.… |